pharmacolog
inhibitor
anthra
one
larg
employ
cjun
ntermin
kinas
inhibitor
studi
evalu
whether
pretreat
abl
prevent
orthopoxvirus
vaccinia
viru
vacv
cowpox
viru
cpxv
modifi
vaccinia
viru
ankara
mva
replic
found
incub
block
virusstimul
jnk
phosphoryl
also
significantli
reduc
viru
product
observ
log
declin
viral
yield
depend
cell
line
infect
reduct
viral
yield
correl
dramat
impact
viru
morphogenesi
progress
intracellular
matur
virus
imv
bare
detect
despit
fact
act
effici
antiorthopoxvir
compound
also
provid
evid
antivir
effect
specif
exert
inhibit
conclus
support
fact
viral
titer
measur
infect
knockout
cell
alter
compar
wildtyp
cell
contrast
declin
viral
titer
verifi
infect
ko
cell
carri
presenc
pharmacolog
inhibitor
focu
recent
studi
evalu
action
divers
viral
infect
includ
dna
virus
data
support
notion
regard
potenti
antipoxvir
compound
orthopoxvirus
encompass
famili
larg
doublestrand
dna
virus
approxim
kbp
size
whose
replic
entir
carri
cytoplasm
infect
cell
condit
et
al
moss
world
health
organ
declar
smallpox
variola
devast
human
diseas
caus
variola
viru
varv
erad
fenner
et
al
barquet
domingo
smith
mcfadden
erad
vaccin
discontinu
consequ
much
world
popul
either
never
immun
immun
year
either
scenario
result
popul
extrem
suscept
variola
poxvirus
laboratori
interest
dissect
poxvirushost
cell
interact
observ
pharmacolog
inhibit
mekerk
pathway
decreas
viru
yield
least
one
order
magnitud
de
et
al
andrad
et
al
moreov
pretreat
cell
pharmacolog
inhibitor
pathway
decreas
vaccinia
viru
vacv
cowpox
viru
cpxv
replic
soar
et
al
show
anthrapyrazolon
inhibitor
cjun
ntermin
kinas
bennett
et
al
caus
signific
decreas
viral
yield
vacv
cpxv
modifi
vaccinia
viru
ankara
mva
although
regard
specif
jnk
inhibitor
bennett
et
al
find
demonstr
antipoxvir
elsevi
bv
effect
mediat
target
yet
undefin
kinas
sinc
prove
effici
vitro
divers
viral
infect
influenza
mehrotra
et
al
rotaviru
holloway
et
al
herpesviru
zapata
et
al
hamza
et
al
perkin
et
al
chen
et
al
propos
potenti
use
compound
treat
poxvirus
infect
complic
associ
vaccin
cell
cultur
antibodi
chemic
cell
clone
deriv
mous
balbc
mous
embryon
fibroblast
mef
wt
doubl
knockout
ko
cell
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
heatinactiv
fetal
bovin
serum
fb
vv
follow
jnk
antibiot
co
fb
purchas
cultilab
campina
sp
brazil
cell
kindli
provid
sogayar
depart
biochemistri
univers
paulo
brazil
davi
howard
hugh
medic
institut
univers
massachusett
medic
school
worcest
gentli
provid
us
wt
ko
cell
follow
rabbit
polyclon
antibodi
purchas
sigmaaldrich
paulo
brazil
anti
btubulin
cell
signal
technolog
beverli
antiphospho
anticjun
antitot
hors
radish
peroxidas
hrp
conjug
antirabbit
antimous
secondari
antibodi
anthra
one
structur
formula
jnk
inhibitor
viii
jnki
viii
n
purchas
calbiochem
paulo
brazil
inhibitor
dilut
dmso
final
concentr
mm
mm
jnki
viii
store
viral
stock
wildtyp
vacv
strain
wr
cpxv
strain
br
propag
vero
cell
mva
propag
cell
virus
highli
purifi
sucros
gradient
sediment
describ
joklik
experi
present
studi
carri
use
intracellular
matur
viru
imv
form
viru
b
viral
infect
cell
allow
reach
confluenc
starv
chang
media
fb
h
cell
infect
indic
multipl
infect
moi
time
shown
need
cell
treat
indic
compound
min
prior
viral
infect
incub
continu
presenc
drug
thirti
five
millimet
dish
ko
cell
densiti
cellsdish
starv
infect
moi
indic
time
h
either
absenc
presenc
lm
jnki
viii
lm
time
point
cultur
wash
cold
pb
cell
disrupt
freezethaw
supernat
collect
viral
yield
quantifi
viral
plaqu
assay
describ
da
silva
et
al
data
confirm
least
three
independ
experi
similar
result
cell
infect
vacv
moi
either
absenc
presenc
lm
incub
h
cell
fix
glutaraldehyd
phosphat
buffer
ph
h
room
temperatur
scrape
gentli
collect
centrifug
cell
wash
cacodyl
buffer
postfix
osmium
tetroxid
dehydr
aceton
process
convent
transmiss
electron
microscopi
thin
section
examin
morgagni
transmiss
electron
microscop
oper
kv
confluent
mm
dish
cell
treat
increas
concentr
lm
h
equal
volum
trypan
blue
stain
ad
well
cell
stain
min
room
temperatur
time
stain
remov
cell
observ
evid
stain
absorpt
indic
cellular
membran
permeabl
death
found
cell
pretreat
lm
stain
concentr
use
throughout
experi
dose
respons
includ
lm
jnki
viii
also
perform
cytotox
assay
lm
employ
experi
lysat
prepar
cell
starv
infect
vacv
cpxv
moi
presenc
absenc
indic
time
cell
wash
cold
pb
disrupt
ice
lysi
buffer
mm
trishcl
ph
triton
mm
edta
glycerol
vv
mm
nacl
mm
navo
sodium
orthovanad
mm
pmsf
phenylmethanesulfonyl
fluorid
lgml
aprotinin
lgml
leupeptin
mm
dtt
whole
cell
lysat
collect
centrifug
rpm
min
protein
concentr
determin
biorad
assay
b
electrophoresi
immunoblot
forti
microgram
protein
per
sampl
separ
electrophoresi
sd
polyacrylamid
gel
transfer
nitrocellulos
membran
de
et
al
briefli
membran
block
room
temperatur
h
pb
contain
wv
nonfat
milk
membran
wash
three
time
pb
contain
incub
specif
polyclon
monoclon
antibodi
pb
contain
wv
bsa
follow
incub
hrpconjug
secondari
antirabbit
ab
antimous
ab
immunoreact
band
visual
ecl
detect
system
describ
manufactur
instruct
ge
healthcar
uk
order
investig
whether
cellular
stress
associ
orthopoxviru
infect
led
activ
stressassoci
protein
kinas
sapk
cjun
ntermin
kinas
jnk
cell
infect
vacv
cpxv
h
postinfect
hpi
whole
cell
lysat
collect
subject
western
blot
evalu
phosphoryl
statu
data
fig
b
demonstr
cpxv
vacv
infect
abl
stimul
phosphoryl
earli
hpi
maxim
level
reach
late
time
infect
cycl
hpi
control
expect
observ
differ
level
infect
addit
viral
stimul
block
dosedepend
manner
lm
fig
lane
vacv
infect
perform
continu
presenc
similar
result
obtain
cpxv
infect
data
shown
order
investig
whether
orthopoxvirusstimul
biolog
relev
viru
perform
multistep
viral
growth
curv
moi
presenc
absenc
cellular
extract
collect
hpi
assay
viral
yield
observ
inhibit
play
relev
role
vacv
cpxv
biolog
signific
reduct
viral
titer
log
reduct
observ
vacv
fig
cpxv
fig
infect
carri
continu
presenc
verifi
inhibitori
effect
associ
restrict
cell
infect
vacv
cpxv
describ
shown
fig
treatment
result
sever
decreas
viral
product
log
reduct
therebi
demonstr
viral
growth
inhibit
celltyp
specif
addit
investig
whether
abl
affect
mva
replic
end
cell
infect
mva
describ
result
show
fig
inhibitor
caus
signific
declin
viru
yield
nearli
log
reduct
mild
decreas
log
infect
note
vacv
cpxv
variat
level
inhibit
caus
might
due
virus
tropism
within
differ
speci
murin
cell
monkey
cell
hamster
cell
order
investig
stage
progress
viral
cycl
affect
cell
left
untreat
fig
b
c
pretreat
inhibitor
fig
e
f
g
infect
vacv
moi
hpi
infect
cell
harvest
examin
electron
microscopi
infect
cell
absenc
inhibitor
panel
b
c
contain
full
spectrum
virion
morphogenesi
form
character
identif
crescent
spheric
immatur
virion
iv
immatur
virion
nucleoid
ivn
brickshap
matur
virion
imv
cell
preincub
panel
e
f
g
show
sever
impair
morphogenesi
progress
larg
virosom
surround
crescent
repeatedli
detect
iv
could
also
observ
howev
ivn
imv
rare
seen
ident
phenotyp
also
observ
cell
infect
cpxv
presenc
data
shown
although
character
specif
jnk
pharmacolog
inhibitor
bennett
et
al
grow
bodi
evid
suggest
may
inhibitor
kinas
well
bain
et
al
bain
et
al
bogoyevitch
arthur
thu
defin
whether
reduct
viral
yield
associ
treatment
direct
consequ
inhibit
wt
fig
ko
mef
cell
fig
infect
vacv
cpxv
infect
carri
either
absenc
presenc
lm
pharmacolog
inhibitor
jnk
jnki
viii
lm
h
infect
cell
collect
assay
viral
product
shown
fig
b
absenc
inhibitor
viral
titer
compar
produc
either
cell
line
wt
jnk
ko
cell
line
observ
strongli
suggest
neither
vacv
cpxv
requir
jnk
product
infect
furthermor
wt
jnk
ko
cell
equal
suscept
refractori
jnki
viii
treatment
order
confirm
jnk
contribut
viral
replic
evalu
phosphoryl
level
substrat
cjun
viral
infect
presenc
absenc
either
jnki
viii
compound
known
revers
atpcompetit
jnk
inhibitor
ultim
block
phosphoryl
jnk
substrat
cjun
bennet
et
al
vivanco
et
al
fig
show
jnki
viii
affect
vacvand
cpxvstimul
cjun
phosphoryl
cjunp
taken
togeth
find
demonstr
even
though
pharmacolog
inhibitor
target
downstream
substrat
jnk
cjun
viral
replic
affect
presenc
thu
data
strongli
suggest
target
kinas
therefor
provid
evid
jnkindepend
inhibitori
action
smallpox
announc
erad
sinc
vaccin
discontinu
consequ
much
world
popul
vulner
therefor
continu
threat
moreov
even
though
smallpox
vaccin
vacv
success
use
erad
program
vaccin
imperfect
safeti
record
use
immunolog
defici
eczema
fenner
et
al
barquet
domingo
smith
mcfadden
furthermor
reemerg
cpxv
europ
vorou
et
al
monkeypox
viru
mpxv
outbreak
africa
unit
state
sejvar
et
al
reynold
et
al
formenti
et
al
emerg
vacv
brazil
fonseca
et
al
damaso
et
al
trindad
et
al
emphas
need
search
new
antipoxvir
compound
potenti
use
clinic
trial
current
antivir
agent
current
approv
fda
food
drug
administr
use
orthopoxvirus
cidofovir
cdv
acycl
nucleosid
phosphon
analogu
known
inhibit
poxviru
replic
also
replic
varieti
dna
virus
herpesviru
adenoviru
papillomaviru
polyomaviru
de
clercq
shown
cidofovir
impair
vaccinia
dna
encapsid
consequ
affect
viral
morphogenesi
jesu
et
al
human
cidofovir
use
success
molluscum
contagiosum
viru
orf
viru
howev
renal
toxic
known
side
effect
caus
drug
de
clercq
importantli
cidofovirresist
strain
camelpox
cowpox
monkeypox
vaccinia
virus
also
isol
smee
et
al
overcom
nephrotox
deriv
form
cdv
gener
test
lipid
conjug
acycl
nucleotid
phosphon
current
phase
ii
clinic
trial
prophylaxi
human
cytomegaloviru
infect
develop
use
anim
rule
smallpox
infect
demonstr
vitro
vivo
efficaci
orthopoxviru
infect
evid
nephrotox
either
anim
human
found
drug
target
viral
dna
polymeras
vacv
strain
shown
cross
resist
well
new
class
antipoxviru
drug
affect
viral
spread
dissemin
also
emerg
one
intens
test
number
orthopoxviru
speci
anim
studi
yang
et
al
b
sbrana
et
al
quenel
et
al
specif
inhibit
viral
protein
requir
format
envelop
viru
form
similar
cdv
viral
resist
confer
point
mutat
dna
polymeras
gene
becker
et
al
also
describ
singl
point
mutat
confer
resist
yang
et
al
b
recent
test
phase
clinic
trial
found
well
toler
safe
healthi
human
jordan
et
al
jordan
et
al
addit
approach
inhibit
viral
multipl
target
cellular
signal
pathway
stimul
requir
success
replic
dissemin
past
year
other
shown
abil
orthopoxvirus
vacv
cpxv
induc
protein
kinas
pathway
provid
adequ
environ
favor
viral
replic
cycl
de
et
al
andrad
et
al
da
silva
et
al
mercer
heleniu
soar
et
al
mcnulti
et
al
also
known
poxvirus
use
src
abl
famili
kinas
activ
modul
intracellular
spread
releas
frischknecht
et
al
reev
et
al
reev
et
al
abl
famili
kinas
mediat
releas
cev
form
eev
reev
et
al
therefor
tyrosin
kinas
inhibitor
origin
develop
treat
cancer
also
test
mani
poxvirus
one
drug
imatinib
mesyl
gleevec
approv
treat
human
cancer
tolomeo
et
al
wolf
rumpold
gleevec
specif
inhibit
abl
famili
kinas
reduc
vacv
dissemin
vivo
reev
et
al
suggest
cardiotox
sideeffect
caus
drug
even
target
cellular
kinas
may
bring
attent
unwant
side
effect
et
al
seem
drug
resist
readili
develop
benefit
antivir
chemotherapi
anthrapyrazolon
inhibitor
cjun
ntermin
kinas
bennett
et
al
bogoyevitch
et
al
focu
manuscript
larg
util
potenti
therapeut
treatment
cancer
diseas
caus
inflamm
neurodegener
sharma
et
al
holm
et
al
hu
liu
de
borst
et
al
wang
et
al
song
et
al
deriv
test
divers
clinic
trial
man
davi
bogoyevitch
et
al
bennett
bogoyevitch
arthur
addit
antivir
effect
investig
divers
viral
model
suggest
jnk
inhibitor
may
provid
new
therapeut
intervent
man
davi
bogoyevitch
arthur
instanc
shown
viral
kinas
kaposi
sarcomaassoci
herpesviru
activ
inhibit
block
viral
gene
express
late
stage
infect
hamza
et
al
varicellazost
viru
vzv
replic
also
decreas
dosedepend
manner
treatment
zapata
et
al
anoth
report
show
inhibit
activ
jnk
hepat
c
viru
protein
contribut
hepat
c
relat
hepatocarcinogenesi
hassan
et
al
furthermor
use
signal
transduct
pathway
modul
either
singli
yang
et
al
b
reev
et
al
combin
could
appropri
therapeut
strategi
fact
shown
use
togeth
inhibitor
phosphatidylinositol
prevent
establish
persist
sarscov
infect
mizutani
et
al
studi
orthopoxvirus
vacv
cpxv
mvacel
hostinteract
found
exert
antivir
effect
result
show
dramat
reduct
viru
yield
infect
perform
presenc
inhibitor
electron
microscop
imag
demonstr
presenc
orthopoxvirus
replic
compromis
normallook
iv
frequent
seen
ivn
rare
imv
could
detect
fig
bottom
panel
consid
specif
pharmacolog
inhibitor
respons
cytokin
stimul
dong
et
al
also
viral
infect
bogoyevitch
arthur
result
show
upon
vacv
cpxv
infect
activ
entir
viral
cycl
inde
inhibit
phosphoryl
dosedepend
manner
fig
howev
block
identifi
viral
cycl
caus
event
occur
independ
sinc
effect
viral
yield
observ
infect
perform
ko
mef
cell
similar
result
found
use
jnki
viii
inhibitor
previou
report
shown
inhibit
cellular
kinas
vitro
bain
et
al
bain
et
al
even
face
concern
rais
specif
inhibitor
sever
studi
still
reli
drug
possibl
therapeut
applic
regard
treatment
human
diseas
furthermor
sinc
discoveri
extens
studi
treatment
numer
nonvir
diseas
murin
model
ikezumi
et
al
gao
et
al
han
et
al
gunawan
et
al
guan
et
al
takamura
et
al
syrkina
et
al
hu
liu
howev
public
work
search
literatur
show
singl
report
demonstr
effect
viral
infect
anim
studi
support
result
observ
cell
cultur
system
furthermor
studi
shown
viral
infect
lead
jnk
activ
inhibit
cellular
kinas
affect
viral
multipl
hamza
et
al
hassan
et
al
zapata
et
al
gupta
et
al
studi
make
strict
connect
inhibit
jnk
impact
viral
infect
jnk
one
kinas
target
drug
addit
analys
inhibitor
cell
line
knockout
kinas
even
rnai
approach
taken
consider
confirm
direct
relationship
therefor
sinc
anim
studi
cost
time
energydepend
system
possibl
research
care
take
step
test
mice
instanc
succeed
correl
data
observ
tissu
cultur
addit
disadvantag
may
consider
offtarget
activ
perhap
poor
solubl
aqueou
solut
orand
possibl
undesir
sideeffect
bennett
et
al
bain
et
al
begleit
et
al
effort
get
around
complic
deriv
develop
celgen
success
complet
phase
trial
healthi
volunt
state
pharmaceut
compani
also
report
phase
ii
evalu
treatment
acut
myelogen
leukemia
also
consid
treatment
respiratori
diseas
robert
der
bogoyevitch
arthur
nevertheless
shortest
path
evalu
vivo
orthopoxviru
infect
would
viral
challeng
murin
model
taken
togeth
question
still
remain
regard
potenti
protein
kinas
target
orthopoxviru
infect
caus
impair
viral
morphogenesi
poxvirus
encod
two
essenti
serinethreonin
kinas
traktman
et
al
lin
et
al
rempel
traktman
lin
broyl
play
function
viral
dna
replic
traktman
et
al
rempel
et
al
domi
beaud
play
role
earli
stage
virion
morphogenesi
wang
shuman
traktman
et
al
protein
repress
inact
none
hallmark
morphogenesi
identifi
therefor
doubt
would
target
one
viral
kinas
addit
viral
protein
play
role
morphogenesi
propos
also
phosphoryl
cellular
kinas
resch
et
al
unger
traktman
wickramasekera
traktman
comparison
electron
microscopi
imag
vacv
mutant
nonpermiss
condit
observ
phenotyp
copi
result
infect
perform
presenc
repress
phosphoprotein
arrest
morphogenesi
stage
iv
format
essenti
imv
seen
ivn
rare
dna
crystalloid
accumul
cytoplasm
unger
traktman
similar
phenotyp
also
seen
major
immunodomin
protein
repress
delet
da
fonseca
et
al
myristoyl
protein
repress
transit
iv
imv
block
ravanello
et
al
thu
far
hard
predict
put
cellular
target
would
affect
viral
morphogenesi
step
prior
subsequ
lead
format
matur
imv
complex
fulli
understood
protein
phosphoryl
proteinprotein
interact
proteolyt
process
event
involv
sinc
cellular
kinas
like
thought
contribut
phosphoryl
viral
protein
plausibl
inhibit
could
affect
event
block
morphogenesi
progress
conclus
result
demonstr
use
inhibit
orthopoxvirus
replic
jnk
independentmann
suggest
cellular
andor
viral
substrat
affect
action
signific
progress
made
discoveri
novel
compound
orthopoxvirus
need
rang
antivir
drug
imper
sinc
occurr
resist
antivir
drug
rare
event
data
support
notion
regard
potenti
antipoxvir
compound
combin
use
antipoxvir
drug
may
enhanc
antivir
activ
perhap
minim
major
side
effect
advantag
reduc
drug
resist
